@article{c401e1b09a414bae8d17a00dda04282a,
title = "C1q and SRPX2 regulate microglia mediated synapse elimination during early development in the visual thalamus but not the visual cortex",
abstract = "The classical complement cascade mediates synapse elimination in the visual thalamus during early brain development. However, whether the primary visual cortex also undergoes complement-mediated synapse elimination during early visual system development remains unknown. Here, we examined microglia-mediated synapse elimination in the visual thalamus and the primary visual cortex of early postnatal C1q and SRPX2 knockout mice. In the lateral geniculate nucleus, deletion of C1q caused a persistent decrease in synapse elimination and microglial synapse engulfment, while deletion of SRPX2 caused a transient increase in the same readouts. In the C1q-SRPX2 double knockout mice, the C1q knockout phenotypes were dominant over the SRPX2 knockout phenotypes, a result which is consistent with SRPX2 being an inhibitor of C1q. We found that genetic deletion of either C1q or SRPX2 did not affect synapse elimination or microglial engulfment of synapses in layer 4 of the primary visual cortex in early brain development. Together, these results show that the classical complement pathway regulates microglia-mediated synapse elimination in the visual thalamus but not the visual cortex during early development of the central nervous system.",
author = "Qifei Cong and Soteros, {Breeanne M.} and Anran Huo and Yang Li and Tenner, {Andrea J.} and Sia, {Gek Ming}",
note = "Funding Information: We thank Matthew Baum (Beth Stevens's Lab, Harvard) for technical advice on eye injections. CRISPR/Cas9 pronuclear injections were performed at the Johns Hopkins Transgenic Core Laboratory, and screening of founders and subsequent work was performed at UTHSCSA. This work was supported by NINDS‐R01NS112389, the William and Ella Owens Medical Research Foundation, the NARSAD Young Investigator grant number 25248, the UTHSCSA Department of Pharmacology, and the Rising STARs award from the University of Texas System to Gek Ming Sia, NIA‐R01AG060148 to Andrea J. Tenner, and startup funding NH21500221 to Qifei Cong. Images were generated at the Core Optical Imaging Facility which is supported by UTHSCSA, NCI‐P30CA54174 (CTRC at UTHSCSA), and NIA‐P01AG19316. Funding Information: We thank Matthew Baum (Beth Stevens's Lab, Harvard) for technical advice on eye injections. CRISPR/Cas9 pronuclear injections were performed at the Johns Hopkins Transgenic Core Laboratory, and screening of founders and subsequent work was performed at UTHSCSA. This work was supported by NINDS-R01NS112389, the William and Ella Owens Medical Research Foundation, the NARSAD Young Investigator grant number 25248, the UTHSCSA Department of Pharmacology, and the Rising STARs award from the University of Texas System to Gek Ming Sia, NIA-R01AG060148 to Andrea J. Tenner, and startup funding NH21500221 to Qifei Cong. Images were generated at the Core Optical Imaging Facility which is supported by UTHSCSA, NCI-P30CA54174 (CTRC at UTHSCSA), and NIA-P01AG19316. Funding Information: National Alliance for Research on Schizophrenia and Depression, Grant/Award Number: 25248; National Cancer Institute, Grant/Award Number: P30CA54174; National Institute of Neurological Disorders and Stroke, Grant/Award Number: R01NS112389; National Institute on Aging, Grant/Award Numbers: P01AG19316, R01AG060148; William and Ella Owens Medical Research Foundation; UTHSCSA; NH21500221; University of Texas System; UTHSCSA Department of Pharmacology Funding information Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",
year = "2022",
month = mar,
doi = "10.1002/glia.24114",
language = "English (US)",
volume = "70",
pages = "451--465",
journal = "GLIA",
issn = "0894-1491",
publisher = "John Wiley and Sons Inc.",
number = "3",
}